Browsing Category
Pharma Industry News
4738 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
How CRISPR Therapeutics’ one-and-done CTX310 therapy could transform treatment for high cholesterol and triglycerides
Find out how CRISPR Therapeutics’ CTX310 gene-editing therapy achieved profound cholesterol and triglyceride reductions — could it reshape cardiovascular care?
Telitacicept delivers breakthrough proteinuria decline in Chinese IgA nephropathy phase 3 study
Find out how RemeGen’s Telitacicept achieved phase 3 success in reducing proteinuria for IgA nephropathy patients in China.
Tenaya Therapeutics’ TN-201 gene therapy shows early success in treating MYBPC3 hypertrophic cardiomyopathy
Discover how Tenaya Therapeutics’ TN-201 gene therapy is showing early signs of transforming treatment for MYBPC3-associated HCM—read more on the trial details and outlook.
Aarti Drugs (NSE: AARTIDRUGS) profit climbs 29% in Q2 FY26 as export-led growth drives margin gains
Aarti Drugs posts 29% YoY profit growth in Q2 FY26 on rising exports and cost discipline. See how backward integration is boosting its margin outlook.
Why Halozyme Therapeutics is raising $1.3bn in convertible notes and what it means for HALO stock
Halozyme Therapeutics raises $1.3B via convertible notes to refinance debt and fund growth. Find out what this means for biotech investors and royalty markets.
Gene therapy dreams on hold? Inside the FDA move that rattled Tenaya Therapeutics
Find out why the FDA paused Tenaya’s TN-201 trial for heart disease and what this could mean for gene therapy investors and the company’s future.
Is Dupixent now the gold standard for asthma with nasal polyps? Inside Sanofi and Regeneron’s big study win
Dupixent outperforms Xolair in phase 4 respiratory trial for chronic rhinosinusitis with asthma. Find out what this means for Sanofi and Regeneron’s growth.
Gilead’s $21bn cancer gamble faces major blow as Trodelvy fails in key breast cancer trial
Gilead’s Trodelvy failed to meet the main goal in a Phase 3 breast cancer trial, raising new questions about its oncology growth strategy.
Why Pfizer’s $10bn Metsera deal could reshape the obesity drug market in 2026 and beyond
Pfizer beats Novo Nordisk in $10B Metsera buyout, reshaping obesity drug competition. Find out what this means for the pharma M&A and GLP-1 space.
Evaxion reports promising immune-biomarker results for AI-designed EVX-01 vaccine with KEYTRUDA
Discover how Evaxion’s AI-powered EVX-01 vaccine drives potent T-cell responses and strengthens its melanoma phase 2 program with KEYTRUDA.